Trials that use: Multiple imputation / missing data
New to this method? Read the tutorial →
20,324 results
- GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy: Complete Statistical AnalysisIndependent statistical analysis of GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02012192).
- Gao Bipolar Spectrum Lithium/Quetiapine Study: Complete Statistical AnalysisIndependent statistical analysis of Gao Bipolar Spectrum Lithium/Quetiapine Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01526148).
- Gao NARASD Lithium Study: Complete Statistical AnalysisIndependent statistical analysis of Gao NARASD Lithium Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02909504).
- Gardasil Vaccination in Post Stem Cell Transplant Patients: Complete Statistical AnalysisIndependent statistical analysis of Gardasil Vaccination in Post Stem Cell Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01092195).
- GARGLESIndependent statistical analysis of Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Garlic4Independent statistical analysis of Effect of Aged Garlic Extract on Atherosclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01534910).
- GARMIndependent statistical analysis of Multifocal Contact Lens Use in Previous Contact Lens Wearers With Near Vision Demands: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Garmin PACT (Physical Activity Tracking in Type 1 Diabetes Using Garmin Vivosmart): Complete Statistical AnalysisIndependent statistical analysis of Garmin PACT (Physical Activity Tracking in Type 1 Diabetes Using Garmin Vivosmart): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gas ChallengeIndependent statistical analysis of Human Cerebral Blood Flow Regulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04265053).
- Gas Exchange Kinetics and Work Load During Exercise: Complete Statistical AnalysisIndependent statistical analysis of Gas Exchange Kinetics and Work Load During Exercise: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03770507).
- Gastrectomy, Eating Behaviour and GLP-1: Complete Statistical AnalysisIndependent statistical analysis of Gastrectomy, Eating Behaviour and GLP-1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02971631).
- Gastric pH and Anthocyanin Absorption: Complete Statistical AnalysisIndependent statistical analysis of Gastric pH and Anthocyanin Absorption: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01122160).
- Gastric Ultrasound in Tube Fed Intubated Patients: Complete Statistical AnalysisIndependent statistical analysis of Gastric Ultrasound in Tube Fed Intubated Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04612348).
- Gastric Ultrasound: Complete Statistical AnalysisIndependent statistical analysis of Gastric Ultrasound: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04127331).
- Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide: Complete Statistical AnalysisIndependent statistical analysis of Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate: Complete Statistical AnalysisIndependent statistical analysis of Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants: Complete Statistical AnalysisIndependent statistical analysis of Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo: Complete Statistical AnalysisIndependent statistical analysis of Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02632812).
- Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02170870).
- GATEWAYIndependent statistical analysis of A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation: Complete Statistical AnalysisIndependent statistical analysis of Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01063049).
- GAVOTTEIndependent statistical analysis of A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS): primary endpoint results, effect…
- GB001 in Adult Participants With Chronic Rhinosinusitis: Complete Statistical AnalysisIndependent statistical analysis of GB001 in Adult Participants With Chronic Rhinosinusitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03956862).
- GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD): Complete Statistical AnalysisIndependent statistical analysis of GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GC-WSIndependent statistical analysis of MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GCBTIndependent statistical analysis of Group Treatment for PTSD: A Randomized Clinical Trial With Veterans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01544088).
- GDCTIndependent statistical analysis of Somatropin Treatment to Final Height in Turner Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00191113).
- GDX-44-016Independent statistical analysis of Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06057168).
- GE-EKGIndependent statistical analysis of Time to Accurate Heart Rate on Neonatal Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04587934).
- Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery: primary endpoint results, effect estimate with confidence interval,…
- Gel-One Treatment in Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Gel-One Treatment in Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01934218).
- GEMIndependent statistical analysis of The GEM (Goals for Eating and Moving) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03006328).
- Gemcabene for the Treatment of Pediatric NAFLD: Complete Statistical AnalysisIndependent statistical analysis of Gemcabene for the Treatment of Pediatric NAFLD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03436420).
- Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00388154).
- Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size…
- Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence…
- Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval,…